Heart Failure
Conditions
Brief summary
Heart failure (HF) is a common and disabling condition in the elderly. Randomized clinical trials and meta-analyses have clearly demonstrated that long-term use of β blockers improves the outcomes of patients with HF. However, limited data have been available on the treatment of HF with preserved ejection fraction (EF) in the elderly. No study has specifically compared the relative effectiveness of carvedilol and nebivolol in treating HF in old age patients with preserved EF.
Detailed description
This trial is a prospective, randomized, open-label, active controlled study designed to investigate effects of nebivolol and carvedilol on diastolic function of the left ventricle (LV) in the elderly HF patients with preserved EF. Patients will be included in the study if they had LVEF ≥ 40%, NYHA functional class I, II or III, and clinical stability without hospital admission for HF in the preceding 3 months.
Interventions
DRUGNebivolol
Nebivolol 10mg, once a day
DRUGCarvedilol
Carvedilol 25mg, twice a day
Sponsors
Menarini Group
Dong-A University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* more than 70 years * EF ≥ 40%
Exclusion criteria
* contraindication to the study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the ratio of transmitral E velocity to early diastolic mitral annular velocity (E/E') | 12 months |
Countries
South Korea
Contacts
Primary ContactYieun-Ji Lee, RN
Outcome results
None listed